BACKGROUND: Inflammatory bowel disease (IBD) pathogenesis involves an inadequately controlled immune reaction to intestinal microbiota, and CD4(+) T cells, dependent on MHC class II (MHC-II) processing and presentation by antigen-presenting cells (APC), play important roles. The role of professional APC (macrophages and dendritic cells [DCs]) and nonprofessional APC (intestinal epithelial cells [IECs]) in microbial-driven intestinal inflammation remains controversial. METHODS: We generated transgenic animals on an MHC-II(-/-) genetic background in which MHC-II is expressed on 1) DC via the CD11c promoter (CD11cTg) or 2) IEC via the fatty acid binding protein (liver) promoter (EpithTg). These mice were crossed with Rag2(-/-) mice to eliminate T and B cells (CD11cTg/Rag2(-/-) and EpithTg/Rag2(-/-)). Helicobacter bilis (Hb) infection and adoptive transfer (AT) of naïve CD4 T cells were used to trigger IBD. RESULTS: CD11cTg/Rag2(-/-) mice infected with Hb+AT developed severe colitis within 3 weeks post-AT, similar to disease in positive control Rag2(-/-) mice infected with Hb+AT. CD11cTg/Rag2(-/-) mice given AT alone or Hb alone had significantly less severe colitis. In contrast, EpithTg/Rag2(-/-) mice infected with Hb+AT developed mild colitis by 3 weeks and even after 16 weeks post-AT had only mild lesions. CONCLUSIONS: MHC-II expression restricted to DCs is sufficient to induce severe colitis in the presence of T cells and a microorganism such as Hb within 3 weeks of AT. Expression of MHC-II solely on IEC in the presence of a microbial trigger and T cells was insufficient to trigger severe colitis.
BACKGROUND:Inflammatory bowel disease (IBD) pathogenesis involves an inadequately controlled immune reaction to intestinal microbiota, and CD4(+) T cells, dependent on MHC class II (MHC-II) processing and presentation by antigen-presenting cells (APC), play important roles. The role of professional APC (macrophages and dendritic cells [DCs]) and nonprofessional APC (intestinal epithelial cells [IECs]) in microbial-driven intestinal inflammation remains controversial. METHODS: We generated transgenic animals on an MHC-II(-/-) genetic background in which MHC-II is expressed on 1) DC via the CD11c promoter (CD11cTg) or 2) IEC via the fatty acid binding protein (liver) promoter (EpithTg). These mice were crossed with Rag2(-/-) mice to eliminate T and B cells (CD11cTg/Rag2(-/-) and EpithTg/Rag2(-/-)). Helicobacter bilis (Hb) infection and adoptive transfer (AT) of naïve CD4 T cells were used to trigger IBD. RESULTS:CD11cTg/Rag2(-/-) mice infected with Hb+AT developed severe colitis within 3 weeks post-AT, similar to disease in positive control Rag2(-/-) mice infected with Hb+AT. CD11cTg/Rag2(-/-) mice given AT alone or Hb alone had significantly less severe colitis. In contrast, EpithTg/Rag2(-/-) mice infected with Hb+AT developed mild colitis by 3 weeks and even after 16 weeks post-AT had only mild lesions. CONCLUSIONS:MHC-II expression restricted to DCs is sufficient to induce severe colitis in the presence of T cells and a microorganism such as Hb within 3 weeks of AT. Expression of MHC-II solely on IEC in the presence of a microbial trigger and T cells was insufficient to trigger severe colitis.
Authors: Sureshkumar Muthupalani; Zhongming Ge; Yan Feng; Barry Rickman; Melissa Mobley; Amanda McCabe; Nico Van Rooijen; James G Fox Journal: Infect Immun Date: 2012-10-01 Impact factor: 3.441
Authors: Charlie C Hsu; Karuna Patil; Audrey Seamons; Thea L Brabb; Piper M Treuting; Jisun Paik; Stacey M Meeker; Lillian Maggio-Price Journal: Comp Med Date: 2020-01-14 Impact factor: 0.982
Authors: Deepa R Jamwal; Daniel Laubitz; Christy A Harrison; Vanessa Figliuolo da Paz; Christopher M Cox; Rachel Wong; Monica Midura-Kiela; Michael A Gurney; David G Besselsen; Prashanth Setty; Lonnie Lybarger; Deepta Bhattacharya; Jean M Wilson; Fayez K Ghishan; Pawel R Kiela Journal: Gastroenterology Date: 2020-06-23 Impact factor: 33.883
Authors: Christoph Thelemann; Remzi Onur Eren; Manuel Coutaz; Jennifer Brasseit; Hanifa Bouzourene; Muriel Rosa; Anais Duval; Christine Lavanchy; Vanessa Mack; Christoph Mueller; Walter Reith; Hans Acha-Orbea Journal: PLoS One Date: 2014-01-28 Impact factor: 3.240
Authors: H J Ren; C L Zhang; R D Liu; N Li; X G Li; H K Xue; Y Guo; Z Q Wang; J Cui; L Ming Journal: Braz J Med Biol Res Date: 2017-04-13 Impact factor: 2.590
Authors: W Zac Stephens; Jason L Kubinak; Arevik Ghazaryan; Kaylyn M Bauer; Rickesha Bell; Kate Buhrke; Tyson R Chiaro; Allison M Weis; William W Tang; Josh K Monts; Ray Soto; H Atakan Ekiz; Ryan M O'Connell; June L Round Journal: Cell Rep Date: 2021-11-02 Impact factor: 9.995
Authors: L A Van Der Kraak; C Schneider; V Dang; A H P Burr; E S Weiss; J A Varghese; L Yang; T W Hand; S W Canna Journal: Mucosal Immunol Date: 2021-06-08 Impact factor: 7.313